Navigation Links
SemBioSys announces first quarter 2008 financial and operational results
Date:5/9/2008

- Canadian Biotechnology Company marks key milestones with insulin and Apo

AI programs -

TSX symbol: SBS

CALGARY, May 9 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced its 2008 first quarter operational and financial results.

Highlights

- Prepared pilot scale quantities of insulin from its facilities and

initiated the final animal toxicology study for safflower-produced

insulin

- Initiated animal studies of the Company's safflower-produced Apo

AI(Milano) that will provide important cholesterol mobilization data,

subsequent to the end of the quarter

- Announced Burt's Bees launched three products containing Hydresia(TM)

in the U.S. personal care market, representing Botaneco's (a wholly-

owned subsidiary of SemBioSys) first national brand name customer

- Received a $350,000 milestone payment from AVAC Ltd. in recognition

of critical advances in the Company's safflower-produced insulin

program and a $500,000 milestone payment from AVAC to support the

commercial activities of Botaneco

- Launched the second generation oleosome product, Hydresia(TM) G2,

subsequent to the end of the quarter

Outlook

SemBioSys is currently conducting all the necessary preclinical work for safflower-produced insulin to enable it to file an IND application with the FDA in the second half of 2008 which would then, pending feedback from the FDA, allow it to proceed into human clinical trials in the second half of 2008. The upcoming insulin milestone events include:

- Submission of an IND to the FDA in the second half of 2008 upon

completion of the toxicology studies of safflower-produced in
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SemBioSys receives milestone payments from AVAC Ltd.
2. SemBioSys initiates toxicology study for safflower-produced insulin
3. SemBioSys announces 2007 financial and operational results
4. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
5. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
6. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
7. SemBioSys signs option agreement for safflower-produced food ingredient
8. SemBioSys announces 2007 third quarter results
9. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
10. SemBioSys updates Apo AI development program
11. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Shimadzu ... new UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength scanning ... instrument is ideal for applications in a variety ... science. , The user-friendly UV-1280 enables intuitive operation, ...
(Date:1/22/2015)... The laboratory information management systems market ... number of technological advancements due to factors such as ... to integrate healthcare systems, and increasing government support for ... integration. Key players in the market focus on technological ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Bulletin Board: ACCP) announced today that it will make ... Conference to be held,November 10-12, 2008 at the New ... scheduled to speak on Tuesday, November 11, 2008 at ... and discuss the Company,s,product opportunities., The presentation will ...
... ROCKVILLE, Md., Nov. 6 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,reported ... September 30,2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), ... approximately $3,501,000,versus $3,520,000 for the comparable period a ...
... safety profile of Ranexa -, - Conference ... -, PALO ALTO, Calif., Nov. 6 ... that the U.S. Food and Drug,Administration (FDA) has ... extended-release tablets) for the treatment of,chronic angina. The ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2EntreMed Reports Third Quarter 2008 Financial Results 2EntreMed Reports Third Quarter 2008 Financial Results 3EntreMed Reports Third Quarter 2008 Financial Results 4EntreMed Reports Third Quarter 2008 Financial Results 5FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 2FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 3FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 4FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c 5
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced today its ... confirm its adherence to current U.S. Food and Drug ... regulated smart device and smart phone application trials utilizing ... "HITLAB is determined to improve global healthcare ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Infectious Diseases (NIAID), part of the National Institutes ... $80 million for two new Regional Centers of ... (RCE). The grants to the University of California, ... the completion of a national network of academic ...
... with implications for pandemic influenza, a new study reports for ... virus can spread from poultry to humans. The research ... Infectious Diseases, now available online. , Crossing the species barrier ... virus with pandemic potential. Previous studies have focused on the ...
... problem of "super-bugs" - bacteria that have become resistant ... high rate of antibiotic prescribing in hospitals contributes to ... antibiotics, an even more important factor contributing to such ... access international medical journal PLoS Medicine, is the use ...
Cached Biology News:New NIAID grants strengthen national biodefense and emerging infectious diseases research network 2Less virulent strains of avian influenza can infect humans 2Agricultural antibiotic use contributes to 'super-bugs' in humans 2
... 400 unique human proteins on a ... proteins, a cross section of all ... for high-quality results. Additional control proteins ... high validity and reproducibility., ,UNIchip protein ...
...
... The benchmark for analytical performance ... ease-of-use and the ultimate in ... Varian 810-MS features include: ... optics minimize,interferences, providing reliable, routine, ...
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
Biology Products: